SR ONE CAPITAL MANAGEMENT, LP Q4 2025 Filing
Filed February 12, 2026
Portfolio Value
$706.4B
Holdings
13
Report Date
Q4 2025
Filing Type
13F-HR
All Holdings (13 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | ZBIOZenas BioPharma, Inc | 5,037,854 | $182.9B | 25.90% | |
| 2 | ACLXArcellx, Inc. | 2,346,630 | $153.0B | 21.66% | |
| 3 | CRSPCRISPR Therapeutics AG | 2,038,763 | $106.9B | 15.14% | |
| 4 | DSGNDesign Therapeutics, Inc. | 6,526,476 | $61.2B | 8.67% | |
| 5 | MLYSMineralys Therapeutics Inc. | 1,563,966 | $56.8B | 8.03% | |
| 6 | SPRYARS Pharmaceuticals, Inc. | 4,012,903 | $46.8B | 6.62% | |
| 7 | ORICORIC Pharmaceuticals, Inc. | 4,514,929 | $37.8B | 5.34% | |
| 8 | ALMSAlumis Inc. | 1,959,896 | $19.1B | 2.71% | |
| 9 | ORKAOruka Therapeutics, Inc | 430,330 | $13.0B | 1.85% | |
| 10 | OCSOculis Holding AG | 641,022 | $12.8B | 1.81% | |
| 11 | ENGNenGene Holdings Inc. | 747,750 | $6.8B | 0.96% | |
| 12 | NKTXNkarta, Inc. | 3,333,333 | $6.2B | 0.87% | |
| 13 | RAREUltragenyx Pharmaceutical Inc. | 137,753 | $3.2B | 0.45% |